[Immunohistochemical study of lung cancer using monoclonal antibody against human pulmonary surfactant apoprotein]. 1991

H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
Department of Pulmonary Surgery, Tokyo National Chest Hospital, Japan.

To evaluate the clinical significance of monoclonal antibody against human pulmonary surfactant apoprotein (S-AP), surgically resected lung cancer from 122 patients was studied. Paraffin embedded tissues were used for the immunohistochemical study by the avidin-biotin-peroxidase complex method. The results were as follows. 1. Adenocarcinoma showed highest immunoreactivity for S-AP compared to the other histologic types. Among subtypes of adenocarcinoma, type II alveolar epithelial type, clara cell type and mixed type of these two types were strongly positive (100%, 77.8% and 66.7% respectively). These results indicate that this antibody may be a good marker for the subtyping of adenocarcinoma. 2. There were some positive cases in other histologic types especially in peripheral type of squamous cell carcinoma. These findings suggest that this antibody was useful for the histological differentiation of lung cancer. 3. As to the immunohistochemical reactivity there was a good correlation between tissue and cytological specimens, which indicate cytological studies may be adequate for this kind of histopathological studies. 4. In our study, there were no patients with S-AP positive carcinomas other than patients with lung cancer. These results indicate that this antibody could be used for the differential diagnosis between primary and secondary lung cancer.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D011663 Pulmonary Surfactants Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI. Surfactants, Pulmonary,Pulmonary Surfactant,Surfactant, Pulmonary
D002276 Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182) Argentaffinoma,Carcinoid,Carcinoid, Goblet Cell,Argentaffinomas,Carcinoid Tumors,Carcinoids,Carcinoids, Goblet Cell,Goblet Cell Carcinoid,Goblet Cell Carcinoids,Tumor, Carcinoid,Tumors, Carcinoid
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001059 Apoproteins The protein components of a number of complexes, such as enzymes (APOENZYMES), ferritin (APOFERRITINS), or lipoproteins (APOLIPOPROTEINS). Apoprotein
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
January 1988, The Tohoku journal of experimental medicine,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
June 1986, Japanese journal of clinical oncology,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
July 1992, Nihon Geka Gakkai zasshi,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
October 1987, Pathology, research and practice,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
November 1985, Cancer research,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
October 1988, Journal of surgical oncology,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
July 1988, Clinical chemistry,
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
October 2010, Hybridoma (2005),
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
July 1990, Zhonghua zhong liu za zhi [Chinese journal of oncology],
H Komatsu, and T Katayama, and K Murakami, and Y Sagara, and K Hayashi
December 1986, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!